Cover Image
市場調查報告書

生技藥品的全球市場:至2027年的趨勢與預測 - 各領域的評估 (單株抗體、胰島素、融合蛋白品質製劑、干擾素、基因治療等)、主要國家市場預測、主要產品分析

Biologics Market Trends and Forecasts to 2027: Evaluation of Therapeutic Segments Including Monoclonal Antibodies, Insulin, Fusion Proteins, Interferons & Gene Therapies, Prediction of Leading National Markets, Investigation of Top Products

出版商 Visiongain Ltd 商品編碼 235218
出版日期 內容資訊 英文 300 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
生技藥品的全球市場:至2027年的趨勢與預測 - 各領域的評估 (單株抗體、胰島素、融合蛋白品質製劑、干擾素、基因治療等)、主要國家市場預測、主要產品分析 Biologics Market Trends and Forecasts to 2027: Evaluation of Therapeutic Segments Including Monoclonal Antibodies, Insulin, Fusion Proteins, Interferons & Gene Therapies, Prediction of Leading National Markets, Investigation of Top Products
出版日期: 2017年11月28日 內容資訊: 英文 300 Pages
簡介

生技藥品,構成癌症、糖尿病、肝炎、自體免疫疾病 (類風濕性關節炎等) 等重症慢性疾病的治療組合中重要的部分。由於盈利高,今後也將維持高市場成長率,不過也不斷面臨新的課題 - 許多產品的專利到期,生物相似藥的登場,國民醫療費的預算削減伴隨的價格降低壓力等 - 。

本報告提供全球生技藥品市場相關調查分析,生技藥品概要,整體市場預測 (今後11年份),各次級市場的詳細預測,主要國家的市場預測,定性分析等系統性資訊。

第1章 報告概要

第2章 生技藥品市場概要主要的概念

  • 生技藥品:大規模複雜的產品
  • 生技藥品開發的歷史沿革
  • 全球醫藥品市場上生技藥品盈利最高的理由
  • 所謂生物相似藥
  • 境界病例
  • 疫苗市場

第3章 全球生技藥品市場

  • 市場預測
  • 生技藥品促進市場成長的要素
  • 高齡化和慢性疾病的增加
  • 暢銷前十種中,8種為生技藥品
  • 生技藥品佔全球醫藥品市場的19%
  • 生物相似藥:機會及威脅
  • 阻礙市場成長要素
  • 成本高,和國民醫療費的預算削減
  • 臨床有效性,不足以填補價格差距的案例
  • 670億美元以上的生技藥品專利,至2020年專利到期
  • 可能不方便的投藥法
  • 生技藥品市場:次市場的預測

第4章 蛋白質製劑次市場的預測

  • 大規模最多樣的次市場
  • 蛋白質從19世紀開始利用於醫療
  • 蛋白質製劑次市場的預測
  • 胰島素次市場
  • 生物相似藥胰島素
  • 其他重組的荷爾蒙:促血紅細胞生長素,G-CSF (顆粒細胞增生因子),人體生長荷爾蒙
  • 血漿、重組的凝血因子
  • 干擾素
  • 酵素置換、其他蛋白質療法的次市場

第5章 單株抗體 (mAb) 次市場的預測

  • 單株抗體次市場:科學性、歷史背景
  • 暢銷醫藥品5種中有3種是單株抗體
  • 自體免疫單株抗體
  • 癌症單株抗體
  • 單株抗體次市場的未來預測 (今後11年份)

第6章 融合蛋白品質製劑次市場的預測

  • 科學性、歷史背景
  • 融合蛋白品質製劑 (FP)的差異化
  • Enbrel
  • Eylea
  • Orencia
  • Nplate
  • Eloctate
  • Nulojix
  • Arcalyst (Regeneron Pharmaceuticals)
  • 融合蛋白品質製劑的開發中產品
  • 融合蛋白品質製劑次市場的未來預測 (今後11年份)

第7章 再生醫療次市場的預測

  • 再生醫療市場明細
  • 再生醫療次市場的未來預測 (今後11年份)
  • 幹細胞治療次市場的未來預測 (今後11年份)
  • 組織工程治療次市場的未來預測 (今後11年份)
  • 基因治療次市場的未來預測 (今後11年份)

第8章 主要國家的生技藥品市場預測

  • 各地區的未來預測 (今後11年份)
  • 美國市場
  • (EU5) 市場歐洲主要5個國家
  • 日本市場
  • 金磚四國市場 (巴西,俄羅斯,印度,中國)

第9章 生技藥品市場、產業的定性分析

  • SWOT分析 (優勢、弱點、機會、威脅)
  • STEP分析:社會、技術性、經濟、政治要素

第10章 結論

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0260

Title:
BIOLOGICS MARKET TRENDS AND FORECASTS TO 2027
Evaluation of Therapeutic Segments Including Monoclonal Antibodies, Insulin, Fusion Proteins, Interferons and Gene Therapies; Prediction of Leading National Markets (US, Japan, EU5 and BRIC); Investigation of Top Products Including Humira, Remicade, Lantus and Enbrel; and Assessment of R&D Including Sirukumab and NurOwn.

Report Details

  • Do you need definitive Biologics market data?
  • Succinct Biologics market analysis?
  • Technological insight?
  • Actionable business recommendations?

Read on to discover how this definitive report can transform your own research and save you time.

Biologics form a vital part of the treatment portfolio for many serious chronic disorders, including cancer, diabetes, hepatitis and autoimmune diseases such as rheumatoid arthritis. This highly lucrative market is set to experience revenue growth to 2027, but will have to adapt to many new challenges along the way. Those challenges include patent expiries on many leading biological drugs, the emergence of biosimilars and cost-restricting measures in the face of limited national healthcare budgets.

Report highlights

155 quantitative tables, charts, and graphs across 300 pages

Analysis of key Biologics in the Market

  • Lantus
  • NovoLog/NovoRapid
  • Humalog
  • Avonex
  • Rebif
  • Humira
  • Remicade
  • Tysabri
  • Herceptin
  • Kadcyla
  • Perjeta
  • Enbrel
  • Eylea
  • OsteoCel Plus
  • Trinity Evolution and Trinity Elite
  • Apligraf
  • Dermagraft
  • IMLYGIC

Global Biologics market outlook and analysis from to 2027

Global Biologics submarket forecasts and analysis from to 2027

  • Protein therapeutics, with sub-forecasting for insulin, other recombinant hormones, plasma and recombinant coagulating factors, interferons, enzyme replacement and other agents
  • Monoclonal antibodies (mAbs)
  • Fusion proteins
  • Regenerative medicine, with sub-forecasting for stem cell treatment, tissue engineering and gene therapy
  • Vaccines

Regional Biologics market forecasts to 2027

  • US forecast to 2027
  • EU5 forecast to 2027
  • Germany forecast to 2027
  • UK forecast to 2027
  • France forecast to 2027
  • Italy forecast to 2027
  • Spain forecast to 2027
  • Japan forecast to 2027
  • BRIC forecast to 2027
  • Brazil forecast to 2027
  • Russia forecast to 2027
  • India forecast to 2027
  • China forecast to 2027

Key questions answered

  • What does the future hold for the Pharmaceutical industry with regards to Biologics?
  • Where should you target your business strategy?
  • Which applications should you focus upon?
  • Which disruptive technologies should you invest in?
  • Which companies should you form strategic alliances with?
  • Which company is likely to success and why?
  • What business models should you adopt?
  • What industry trends should you be aware of?

Target audience

  • Leading Pharmaceutical companies
  • Suppliers
  • Contractors
  • Technologists
  • R&D staff
  • Consultants
  • Analysts
  • CEO's
  • CIO's
  • COO's
  • Business development managers
  • Investors
  • Governments
  • Agencies
  • Banks

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Biologics Overview
  • 1.2. Why you Should Read this Report
  • 1.3. How this Report Delivers
  • 1.4. Main Questions Answered by this Report
  • 1.5. Who is this Report for?
  • 1.6. Research and Analysis Methods
  • 1.7. Frequently Asked Questions (FAQ)
  • 1.8. Some Associated Reports
  • 1.9. About Visiongain

2. Introduction to the Biologics Market and Key Concepts

  • 2.1. Biologics: Large and Complex Products
  • 2.2. A Brief History of Biological Drug Development
  • 2.3. Why are Biologics the Most Lucrative Products in the Global Pharmaceutical Market?
  • 2.4. What are Biosimilars?
    • 2.4.1. Brief History of Biosimilars
    • 2.4.2. What are Interchangeable Biological Products and how do They Differ from Biosimilars?
    • 2.4.3. Why Many Nations Oppose Automatic Substitution of Reference Biologics with Biosimilars
  • 2.5. Marginal Cases
  • 2.6. Vaccines Market

3. The Global Biologics Market to 2027

  • 3.1. The Global Biologics Market Forecast, to 2027
  • 3.2. What Factors Will Drive Growth in the Biologics Market?
  • 3.3. Ageing Population and the Rise of Chronic Disease
  • 3.4. Eight of the Top Ten Best-Selling Drugs in 2015 were Biologics
  • 3.5. Biologics Constitute 19% of the Global Pharmaceutical Market - Further Launches Will Drive Market
  • 3.6. Biosimilars - Both an Opportunity and a Threat
  • 3.7. What Factors Will Restrain Growth in the Biologics Market?
  • 3.8. High Costs in the Face of Declining National Healthcare Budgets
  • 3.9. In Some Areas, Clinical Efficacy is not Superior Enough to Justify the Price Gap
  • 3.10. Over $67bn worth of Biologic Patents due to Expire by 2020
  • 3.11. Administration is Often not as Convenient
  • 3.12. Biologics Market: Submarket Forecasts to 2027

4. Protein Therapeutics Submarket to 2027

  • 4.1. Largest and Most Diverse Submarket
  • 4.2. Proteins have been used Medicinally since the 19th Century
    • 4.2.1. Recombinant DNA Technology - The Major Breakthrough in the use of Protein Drugs
  • 4.3. Protein Therapeutics Submarket Forecast to 2027
  • 4.4. Insulin Submarket to 2027
    • 4.4.1. The First Protein Therapeutic
    • 4.4.2. 430 Million People Expected to be Diagnosed with Diabetes by 2030
    • 4.4.3. The Status of the Market in 2016: Novo Nordisk, Sanofi and Eli Lilly Dominate
    • 4.4.4. Insulin Submarket Forecast to 2027
    • 4.4.5. Lantus: The Market Leading Drug by Far
      • 4.4.5.1. Lantus Revenue Forecast to 2027
    • 4.4.6. NovoLog/NovoRapid Revenue Forecast to 2027
    • 4.4.7. Humalog Revenue Forecast to 2027
    • 4.4.8. New Approvals and Pipeline
      • 4.4.8.1. Tresiba (Novo Nordisk)
      • 4.4.8.2. BIOD-123 (Biodel)
  • 4.5. Biosimilar Insulin
    • 4.5.1. Approved Insulin Biosimilars
    • 4.5.2. Abasaglar/Basaglar/Insulin Glargine BS - The First Insulin Biosimilars to be Approved in Developed Markets. Delayed in the US
  • 4.6. Other Recombinant Hormones: Erythropoietins, G-CSF and Human Growth Hormone
    • 4.6.1. Erythropoietin
    • 4.6.2. First-Generation Therapies Launched in the 1980s
      • 4.6.2.1. Aranesp: Slowly Growing
      • 4.6.2.2. Epogen: Increases in Selling Price are No Longer Enough to Ward off Decline
      • 4.6.2.3. Procrit/Eprex: In Decline Since 2013
      • 4.6.2.4. NeoRecormon and Mircera (Roche) Provides Competition for Market Leader Amgen
      • 4.6.2.5. Safety Concerns for Erythropoietin-Stimulating Agents is Leading to Decreased Demand
      • 4.6.2.6. The Challenge from Oral Therapies is Coming
      • 4.6.2.7. Treating Anaemia in Patients with CKD - The Leading Use of EPO Therapies
      • 4.6.2.8. Many Biosimilar Epoetins Approved Around the World
    • 4.6.3. G-CSF
    • 4.6.4. G-CSF: Discovered 1983. Recombinant Forms Available Since 1991
      • 4.6.4.1. Amgen Leads the Market
      • 4.6.4.2. Neupogen and Neulasta Revenues, and the Onpro Kit
      • 4.6.4.3. Teva Aiming to Challenge Amgen's Dominance
      • 4.6.4.4. Facing Much Biosimilar Competition Around the World
    • 4.6.5. Human Growth Hormone
      • 4.6.5.1. Human Growth Hormone: First Extracted in 1958
      • 4.6.5.2. Novo Nordisk Dominates Market
      • 4.6.5.3. Novo Nordisk Aiming to Retain Dominance Through FlexPro Device and NN8640. Somatropin Candidate
      • 4.6.5.4. Multiple Biosimilars Available - Omnitrope is Market Leader
      • 4.6.5.5. Biosimilar Growth Hormones in Asia
    • 4.6.6. Other Recombinant Hormones Submarket Forecast to 2027
  • 4.7. Plasma and Recombinant Coagulating Factors
    • 4.7.1. Discovery of Plasma and Clotting Proteins
    • 4.7.2. Types of Recombinant Factor
    • 4.7.3. Clotting Factor Deficiency Diseases
    • 4.7.4. Baxter/Baxalta: Entered the Bleeding Disorders Market in 1992, Markets Various Leading Products
      • 4.7.4.1. Baxter: New Product Launches Include Rixubis and Obizur
    • 4.7.5. Novo Nordisk: Committed to Remaining a Leading Company in the Bleeding Disorders Market
      • 4.7.5.1. Novo Nordisk: Has filed for Approval for N9-GP and NovoEight is Doing Well
    • 4.7.6. Bayer: Markets Kogenate, Kogenate FS, and has Received FDA Approval for Kovaltry
    • 4.7.7. Limited Opportunities for Biosimilar Challenge
    • 4.7.8. Plasma and Recombinant Coagulating Factors Submarket Forecast to 2027
  • 4.8. Interferons
    • 4.8.1. Interferons: Key Antiviral and MS Therapies Since the 1990s
    • 4.8.2. Interferons for Treating Hepatitis: Its Influence is Decreasing
    • 4.8.3. Competition from Oral Protease and Polymerase Inhibitors
      • 4.8.3.1. Oral Therapies are Expensive
    • 4.8.4. Avonex: The Leading Interferon Therapy
      • 4.8.4.1. Avonex Revenue Forecast to 2027
    • 4.8.5. Rebif: Merck Attempting to Differentiate Rebif from Other Interferon Therapies
      • 4.8.5.1. Rebif Revenue Forecast to 2027
    • 4.8.6. Betaseron
    • 4.8.7. Plegridy: New Therapy with High Potential
    • 4.8.8. Biosimilar Interferons: None Approved in Developed Markets, but Many Available in Emerging Nations
    • 4.8.9. Interferon Submarket Forecast to 2027
  • 4.9. Enzyme Replacement and Other Protein Therapies Submarket
    • 4.9.1. Cerezyme: Genzyme's Leading Enzyme Replacement Therapy
    • 4.9.2. Myozyme and Lumizyme
    • 4.9.3. Fabrazyme and Aldurazyme
    • 4.9.4. Botulinum Toxin Brands Include Botox, Dysport and Xeomin
    • 4.9.5. Other Protein Therapeutics Pipeline
      • 4.9.5.1. Anthera Buys Sollpura from Eli Lilly, Phase 3 Results Expected Q4 2016
      • 4.9.5.2. Multikine (CEL-SCI)
      • 4.9.5.3. Vonapantiase (Proteon Therapeutics)
    • 4.9.6. Enzyme Replacement and Other Protein Therapeutics Submarket Forecast to 2027

5. Monoclonal Antibodies Submarket to 2027

  • 5.1. Monoclonal Antibodies Submarket: Scientific and Historical Background
    • 5.1.1. Natural Antibodies: Key to the Immune System
    • 5.1.2. From Serum Therapy to Monoclonal Antibodies
    • 5.1.3. Humanising the mAb
    • 5.1.4. MAbs have found Success in Treating Autoimmune Disorders, Cancers and Others Diseases - Great Potential for the Future
    • 5.1.5. MAbs for All? Technologies Come Off Patent
  • 5.2. Three out of the Top Five Best-Selling Drugs are mAbs
  • 5.3. Autoimmune mAbs
    • 5.3.1. Past Approvals
    • 5.3.2. Humira - The World's Best-Selling Prescription Drug
      • 5.3.2.1. AbbVie Plans to Drive Growth Through New Indications
      • 5.3.2.2. Positive Opinion from CHMP for Treatment of Non-Infectious Uveitis
      • 5.3.2.3. Recently Approved for Hidradenitis Suppurativa in the US, Europe, and Japan
      • 5.3.2.4. Biosimilar Adalimumab: Patents Protect Humira in Developed Markets for Now
      • 5.3.2.5. Humira Revenue Forecast to 2027
    • 5.3.3. Remicade: Second Only to Humira
    • 5.3.4. 2016. Revenue for J&J and Merck
      • 5.3.4.1. Has Defended Revenues well but now Has to Deal with Biosimilar Competition
      • 5.3.4.2. Patent Dance in US
      • 5.3.4.3. Biosimilar Infliximab: Multiple Launches
      • 5.3.4.4. Remicade Revenue Forecast to 2027
    • 5.3.5. Stelara: Blockbuster Status Well Established
      • 5.3.5.1. Stelara Revenues 2014-2016
      • 5.3.5.2. Orphan Drug Designation for paediatric Crohn's Disease
    • 5.3.6. Simponi and Simponi Aria: Another Blockbuster mAb for J&J and Merck & Co.
      • 5.3.6.1. 2015 and 2014 Revenue Breakdown
    • 5.3.7. Tysabri: Blockbuster Drug's High Efficacy Offsets its Risks
      • 5.3.7.1. Tysabri: Revenues 2012-2016
      • 5.3.7.2. Tysabri Revenue Forecast to 2027
    • 5.3.8. Xolair: New Indication, and Revenue Breakdown
    • 5.3.9. Actemra/RoActemra: Strong Growth in All Regions
    • 5.3.10. Cimzia: Blockbuster Which has been Used by Over 90,000 Patients
    • 5.3.11. Autoimmune mAbs Pipeline: RA is the Main Target
      • 5.3.11.1. Sarilumab (REGN88/SAR153191) by Regeneron and Sanofi: BLA Accepted for Review and Decision Expected by November 2016
      • 5.3.11.2. Sirukumab (CNTO-136) by J&J and GSK: Multiple Phase 3 Studies Around the World
      • 5.3.11.3. Clazakizumab: Developed by Alder Biopharmaceuticals and BMS but now Licensed to Vitaeris
      • 5.3.11.4. Tregalizumab (BT-061) by Biotest: AbbVie Backs out After Poor Results
      • 5.3.11.5. Mavrilimumab by AstraZeneca: Approaching Phase 3
      • 5.3.11.6. Zinbryta (daclizumab high-yield process) by Biogen and AbbVie: Positive Opinion from CHMP
      • 5.3.11.7. Lebrikizumab by Roche: Undergoing Phase 3 After Positive Phase 2b Results
      • 5.3.11.8. Sifalimumab (MEDI-545) by AstraZeneca: Hasn't Made the Cut for Phase 3
      • 5.3.11.9. Anifrolumab by AstraZeneca
  • 5.4. Oncology mAbs
    • 5.4.1. Past Approvals
    • 5.4.2. Rising Incidence of Cancer Will Drive Demand
    • 5.4.3. Rituxan: The World's Leading Anti-Cancer mAb
    • 5.4.4. Biosimilar Rituximab: Two Candidates Await Approval in Europe
    • 5.4.5. Gazyva: Roche's Successor to Rituxan, Will Help to Retain Revenues in Face of Biosimilar Competition
      • 5.4.5.1. Approval for Follicular Lymphoma and Being Investigated for Other Indications
    • 5.4.6. Avastin: Growing under CER, Through New Indications
      • 5.4.6.1. Controversy over Off-Label Avastin use: Roche is Backed up by Incidents in India, and Opinion of EFPIA
      • 5.4.6.2. Biosimilar Bevacizumab: Late Patent Expiry is a Blessing for Roche, Although Various Biosimilars in Development
    • 5.4.7. Herceptin: Breast Cancer Blockbuster
      • 5.4.7.1. Pricing Challenges in Emerging Markets, and 2016 Revenues
      • 5.4.7.2. Roche Builds Franchise of Anti-HER2 mAbs Around Herceptin
      • 5.4.7.3. Herceptin Revenue Forecast to 2027
      • 5.4.7.4. Biosimilar Trastuzumab
    • 5.4.8. Kadcyla
      • 5.4.8.1. Mixed Results from Different Clinical Trials
      • 5.4.8.2. Kadcyla Sales Forecast to 2027
    • 5.4.9. Perjeta
      • 5.4.9.1. Positive Results from Different Clinical Trials
      • 5.4.9.2. Perjeta Revenue Forecast to 2027
    • 5.4.10. Yervoy: Bristol-Myers Squibb's Leading Anti-Cancer mAb, KeepsHigh Revenues, but with Decline over 2015
    • 5.4.11. Opdivo: Big Potential for Bristol-Myer Squibb's PD-1 Inhibitor
      • 5.4.11.1. Good News and Bad News for NSCLC from CheckMate Trials
      • 5.4.11.2. Cyramza (Eli Lilly): Approved in Three Additional Indications Since its First Approval in April 2014
    • 5.4.12. Oncology mAbs: New Approvals and Pipeline
      • 5.4.12.1. Empliciti (Elotuzumab) by Bristol-Myers Squibb and AbbVie): Recently Approved
      • 5.4.12.2. Avelumab: Pfizer and Merck KGaA Team Up to Develop Their Own Anti-PD mAb
      • 5.4.12.3. Unituxin (United Therapeutics) Receives FDA Approval March 2015
      • 5.4.12.4. SAR3419 (coltuximab ravtansine) (anti-CD19, Sanofi)
  • 5.5. Monoclonal Antibodies Submarket Forecast to 2027

6. Fusion Proteins Submarket to 2027

  • 6.1. Scientific and Historical Background
  • 6.2. Differentiating Fusion Proteins
  • 6.3. Enbrel: The First FP to be Approved, in 1998
    • 6.3.1. Gradually Approved for Additional Indications
    • 6.3.2. The Leading Fusion Protein
    • 6.3.3. Enbrel Granted Extended Patent Protection in the US, Patent has Expired in EU
    • 6.3.4. Multiple Biosimilars Available in Emerging Markets
    • 6.3.5. Enbrel Revenue Forecast to 2027
  • 6.4. Eylea: Blockbuster FP Treatment for Wet AMD
    • 6.4.1. Eylea Revenue Forecast to 2027
  • 6.5. Orencia: Grows Blockbuster Revenues for Second Year in a Row
  • 6.6. Nplate: Generates Half a Billion in Revenues for Amgen
  • 6.7. Eloctate: Approved June 2014, Fulfils Unmet Need in the Haemophilia Community
  • 6.8. Nulojix: Bristol-Myers Squibb's Therapy for Preventing Organ Rejection
  • 6.9. Arcalyst by Regeneron Pharmaceuticals: For Very Rare Conditions
  • 6.10. Fusion Proteins Pipeline
    • 6.10.1. Trebananib (Amgen)
    • 6.10.2. Sotatercept by Acceleron Pharma and Celgene Corporation - Currently Undergoing Eight Clinical Trials
    • 6.10.3. Blisibimod (Anthera Pharmaceuticals) for the Treatment of Various Autoimmune Diseases, in Late Stage Development
  • 6.11. Fusion Protein Submarket Forecast to 2027

7. Regenerative Medicines Submarket to 2027

  • 7.1. Regenerative Medicines Market Breakdown
  • 7.2. Regenerative Medicines Submarket Forecast, to 2027
  • 7.3. Stem Cell Therapies Submarket, to 2027
    • 7.3.1. Stem Cells: Scientific Breakdown
    • 7.3.2. Stem Cell Therapies Submarket Breakdown
    • 7.3.3. Haematopoietic Stem Cell Transplantation: Over 95,000 Carried out in 2016
      • 7.3.3.1. From Procedures to Products: Cord Blood Stem Cell Approvals
    • 7.3.4. Osteocel Plus: The Leading Stem Cell Orthobiologic
      • 7.3.4.1. Osteocel Plus Revenue Forecast to 2027
    • 7.3.5. Trinity Evolution and Trinity Elite
      • 7.3.5.1. Trinity Evolution and Trinity Elite Revenue Forecast to 2027
    • 7.3.6. MSC-100-IV (Previously Known as Prochymal): World's First Approved Stem Cell Drug Outside of South Korea
      • 7.3.6.1. An Important Role to Play in the Future of HSCT, and also Wins Approval in Japan through Partner
    • 7.3.7. CARTISTEM (MEDIPOST): The World's First Allogeneic Stem Cell Drug
    • 7.3.8. Hearticellgram-AMI (PharmaCell B.V.): One of the First Approved Cardiovascular Stem Cell Treatments in the World
    • 7.3.9. Stem Cell Therapies Pipeline
      • 7.3.9.1. Cx601 by TiGenix: Marketing Authorisation Application has been Submitted to EMA
      • 7.3.9.2. CardiAMP (BioCardia) for Heart Failure: Undergoing Phase 3 Trial and has Received Grant from MSCRF
      • 7.3.9.3. NurOwn (BrainStorm Cell Therapeutics): Neurotrophic Factor -Releasing Stem Cells for ALS in Phase 2. and Due to end Soon
      • 7.3.9.4. Agenmestencel-T (Apceth): Phase 1/2 Due to end Soon
    • 7.3.10. Stem Cell Therapies Submarket Forecast to 2027
  • 7.4. Tissue Engineering Therapies Submarket to 2027
    • 7.4.1. Tissue Engineering - In Vitro Manipulation for Therapeutic Purposes
    • 7.4.2. Current Status of the Market
    • 7.4.3. Apligraf: The Leading Product
      • 7.4.3.1. Apligraf Revenue Forecast to 2027
    • 7.4.4. Dermagraft: Organogenesis Further Strengthens Position Through this 2014 Acquisition
      • 7.4.4.1. Dermagraft Revenue Forecast to 2027
    • 7.4.5. ReCell
    • 7.4.6. MySkin and CyroSkin
    • 7.4.7. Tissue Engineering Therapies Pipeline
      • 7.4.7.1. NeoCart by Histogenics: Undergoing Phase 3 Trial for Knee Cartilage Repair
      • 7.4.7.2. Extracorporeal Bio-Artificial Liver Therapy by Vital Therapies
      • 7.4.7.3. StrataGraft by Stratatech Corporation Demonstrates Positive Top-Line Results
    • 7.4.8. Tissue Engineering Therapies Submarket Forecast to 2027
  • 7.5. Gene Therapies Submarket to 2027
    • 7.5.1. Gene Therapy: Historical and Scientific Background
    • 7.5.2. Harnessing Infectivity: Viral Vectors in Gene Therapy
    • 7.5.3. Approved Gene Therapy Products
      • 7.5.3.1. Gendicine: The World's First Commercial Gene Therapy Product
      • 7.5.3.2. Oncorine: First Oncolytic Viral Therapy
      • 7.5.3.3. Neovasculgen: Russia's First Gene Therapy
      • 7.5.3.4. Neovasculgen: Drop in Revenues in 2015, but HSCI Predicts Notable Increases as Product is Added to VED List
      • 7.5.3.5. Glybera: The First Gene Therapy for Western Markets, Although Has Abandoned Hope of Receiving FDA-Approval
    • 7.5.4. IMLYGIC
      • 7.5.4.1. IMLYGIC: Clinical Trials and Development Efforts
      • 7.5.4.2. IMLYGIC: Revenue Forecast to 2027
    • 7.5.5. Gene Therapies Pipeline
      • 7.5.5.1. AAV2-hRPE65v2 (Spark Therapeutics): Undergoing Phase 3 Trial
      • 7.5.5.2. AdV-tk/ProstAtak (Advantagene): Phase 3
      • 7.5.5.3. Collategene (beperminogene perplasmid, AMG0001) - (AnGes MG/Vical)
    • 7.5.6. Gene Therapy Submarket Forecast to 2027

8. Leading National Markets for Biologics to 2027

  • 8.1. Regional Forecasts for the Global Biologics Market to 2027
  • 8.2. US Biologics Market to 2027
    • 8.2.1. The Major National Market
    • 8.2.2. Value-Based Pricing in the US
    • 8.2.3. Regulation of Biologics in the US
    • 8.2.4. US Biosimilars Market
      • 8.2.4.1. FDA Finalises Biosimilar Guidelines and Biosimilar Naming
    • 8.2.5. US Biologics Market Forecast to 2027
  • 8.3. EU5. Biologics Market to 2027
    • 8.3.1. Current Composition and Future Outlook
    • 8.3.2. European Biosimilar Market
      • 8.3.2.1. History of EMA Guidelines and Updates
    • 8.3.3. EU5. Market Forecast by Nation to 2027
  • 8.4. Japanese Biologics Market to 2027
    • 8.4.1. Current Status of the Japanese Biologics Market
    • 8.4.2. Japanese Biosimilar Market
    • 8.4.3. Japanese Biologics Market Forecast to 2027
  • 8.5. BRIC National Biologic Markets to 2027
    • 8.5.1. BRIC Markets Overview
    • 8.5.2. BRIC Biologic Market Forecast to 2027
      • 8.5.2.1. Unique Challenges Faced by the Biologics Industry have led to Current Composition of the BRIC Biologic Market
      • 8.5.2.2. Future Outlook
      • 8.5.2.3. BRIC Nation Market Shares in the Global Biologics Market will Nearly Double During the Forecast Period
    • 8.5.3. Brazil: Disproportionately High Government Spending on Biologics
      • 8.5.3.1. Brazilian Government Eager to Promote Domestic Biologic and Biosimilar Development
    • 8.5.4. Russia: Another Government Which is Eager to Increase Domestic Biological Drug Development
    • 8.5.5. India: Biologics Market Behind that of Other BRIC Nations, but Biosimilars Submarket Thriving
      • 8.5.5.1. CDSCO Guidelines Released in 2012
    • 8.5.6. China: Expected to the Largest BRIC Market for Biologics by 2020
      • 8.5.6.1. The Largest National Biosimilar Market in the World

9. Qualitative Analysis of the Biologics Market and Industry

  • 9.1. SWOT Analysis of the Global Biologics Market and Industry
    • 9.1.1. Strengths
    • 9.1.2. Opportunities
    • 9.1.3. Weaknesses
    • 9.1.4. Threats
  • 9.2. STEP Analysis of the Global Biologics Market and Industry
    • 9.2.1. Social Factors
    • 9.2.2. Technological Developments
    • 9.2.3. Economic Pressures
    • 9.2.4. Political Issues

10. Conclusions

  • 10.1. Biologics Market to Achieve Steady Growth Throughout the Forecast Period
  • 10.2. Changes in Market Composition: mAbs to Become Leading Submarket
  • 10.3. The Emergence of Biosimilars
  • 10.4. Challenges for the Market
  • Visiongain Report Sales Order Form
  • Some Associated Reports
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form

List of Figures

  • Figure 1.1: Forecasted Submarkets of the Biologics Market
  • Figure 3.1: Global Biologics Market Forecast: Revenues ($bn), to 2027
  • Figure 3.2: Submarkets within the Biologics Market Forecast: Revenues ($bn),2016-2027
  • Figure 4.1: Protein Therapeutics Submarket Forecast: Revenues ($bn), to 2027
  • Figure 4.2: Diabetes Prevalence in Leading National Markets, 2014
  • Figure 4.3: Insulin Submarket Forecast: Revenues ($bn), to 2027
  • Figure 4.4: Lantus Revenue Forecast: Revenues ($bn), to 2027
  • Figure 4.5: NovoLog/NovoRapid Revenue Forecast: Revenues ($bn) to 2027
  • Figure 4.6: Humalog Revenue Forecast: Revenues ($bn), to 2027
  • Figure 4.7: Other Recombinant Hormones Submarket Forecast: Revenues ($bn),to 2027
  • Figure 4.8: Plasma and Recombinant Coagulating Factors Submarket Forecast: Revenues ($bn), to 2027
  • Figure 4.9: Avonex Submarket Forecast: Revenues ($bn), to 2027
  • Figure 4.10: Rebif Revenue Forecast: Revenue ($bn), to 2027
  • Figure 4.11: Interferon Submarket Forecast: Revenues ($bn), to 2027
  • Figure 4.12: Enzyme Replacement and Other Protein Therapeutics Submarket Forecast: Revenues ($bn), to 2027
  • Figure 5.1: Humira Revenue Forecast: Revenue ($bn),to 2027
  • Figure 5.2: Remicade Revenue Forecast: Revenue ($bn),to 2027
  • Figure 5.3: Stelara Revenue 2014-2016: Revenue ($bn)
  • Figure 5.4: Total TysabriRevenues 2012-2016, Revenues ($m)
  • Figure 5.5: Tysabri Revenue Forecast: Revenue ($m), to 2027
  • Figure 5.6: Herceptin Revenue Forecast: Revenue ($bn),to 2027
  • Figure 5.7: Kadcyla Revenue Forecast: Revenue ($m), to 2027
  • Figure 5.8: Perjeta Revenue Forecast: Revenue ($bn), to 2027
  • Figure 5.9: Monoclonal Antibodies Submarket Forecast: Revenue ($bn),to 2027
  • Figure 6.1: Enbrel Revenue Forecast: Revenue ($bn), to 2027
  • Figure 6.2: Eylea Revenue Forecast: Revenue ($bn), to 2027
  • Figure 6.3: Fusion Proteins Forecast: Revenue ($bn), to 2027
  • Figure 7.1: Regenerative Medicines Market Forecast: Revenue ($bn), to 2027
  • Figure 7.2: Osteocel Plus Revenue Forecast: Revenue ($bn), to 2027
  • Figure 7.3: Trinity Evolution and Trinity Elite Revenue Forecast: Revenue ($m), to 2027
  • Figure 7.4: Stem Cell Therapies Market Forecast: Revenue ($bn), to 2027
  • Figure 7.5: Apligraf Revenue Forecast: Revenue ($m), to 2027
  • Figure 7.6: Dermagraft Revenue Forecast: Revenue ($m),to 2027
  • Figure 7.7: Tissue Engineering Therapies Submarket: Revenues ($bn), to 2027
  • Figure 7.8: IMLYGIC Revenue Forecast: Revenue ($m), to 2027
  • Figure 7.9: Gene Therapies Market Forecast: Revenue ($bn), to 2027
  • Figure 8.1: Regional Breakdown of Global Biologics Market: Revenues ($bn), Market Share (%), 2016
  • Figure 8.2: Regional Breakdown of Global Biologics Market: Revenues ($bn), Market Share (%), 2027
  • Figure 8.3: Regional Forecasts for Global Biologics Market: Revenues ($bn),to 2027
  • Figure 8.4: US Biologics Market: Revenues ($bn),to 2027
  • Figure 8.5: EU5 Market Breakdown: Market Share (%), 2016
  • Figure 8.6: EU5 Biologics Market: Revenues ($bn), to 2027
  • Figure 8.7: Japanese Biologics Market: Revenues ($bn), to 2027
  • Figure 8.8: Biologics Market Breakdown: Revenues ($bn), Market Share (%), 2016
  • Figure 8.9: BRIC Biologics Market: Revenues ($bn), to 2027
  • Figure 8.10: Biologics Market Breakdown: Revenues ($bn), Market Share (%), 2027
  • Figure 9.1: SWOT Analysis of Biologics Market and Industry, to 2027
  • Figure 9.2: STEP Analysis of Biologics Market and Industry, to 2027
  • Figure 10.1: Global Biologics Market Forecast: Revenues ($bn), Annual Growth Rate (%), to 2027
  • Figure 10.2: Breakdown by Submarket: Revenues ($bn), to 2027

List of Tables

  • Table 1.1: Currency Exchange Rates: Average Exchange Rate to USD for 2015 and 2016
  • Table 2.1: First Approvals for Recombinant Protein Therapies, 1982-1993
  • Table 3.1: Global Biologics Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 3.2: Global Biologics Market Forecast: Revenues ($bn), AGR (%), CAGR (%),2021-2026
  • Table 3.3: Top Ten Best-Selling Drugs in 2016: Revenue ($bn), Share of Biologics Market (%)
  • Table 3.4: Patent Status of Selected Leading Biologics
  • Table 3.5: Submarkets within the Biologics Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2021
  • Table 3.6: Submarkets within the Biologics Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2022-2027
  • Table 4.1: First Approvals for Recombinant Protein Therapies,1982-1993
  • Table 4.2: Protein Therapeutics Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 4.3: Protein Therapeutics Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2022-2027
  • Table 4.4: Diabetes Prevalence in Leading National Markets, 2014
  • Table 4.5: Insulin Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 4.6: Insulin Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2022-2027
  • Table 4.7: Lantus Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 4.8: Lantus Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%),2022-2027
  • Table 4.9: NovoLog/NovoRapid Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 4.10: NovoLog/NovoRapid Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%), 2022-2027
  • Table 4.11: Humalog Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%),2016-2021
  • Table 4.12: Humalog Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%),2022-2027
  • Table 4.13: Selected Insulin Biosimilars which have been Approved and Launched
  • Table 4.14: Selected EPO Biosimilars Approved in India
  • Table 4.15: European Biosimilar Approvals: G-CSF
  • Table 4.16: Selected Filgrastim Biosimilars Approved Worldwide, 2016
  • Table 4.17: Other Recombinant Hormones Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 4.18: Other Recombinant Hormones Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2022-2027
  • Table 4.19: Selected Coagulating Factors Significant in Segment
  • Table 4.20: Plasma and Recombinant Coagulating Factors Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 4.21: Plasma and Recombinant Coagulating Factors Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%),2022-2027
  • Table 4.22: Selected Approved Branded Interferon Therapies
  • Table 4.23: Avonex Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 4.23: Avonex Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), to 2027
  • Table 4.25: Rebif Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2021
  • Table 4.26: Rebif Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027
  • Table 4.27: Selected Interferon Alfa Biosimilars Approved Worldwide, 2016-2017
  • Table 4.28: Selected Interferon Beta Biosimilars Approved Worldwide,2016-2017
  • Table 4.29: Interferon Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 4.30: Interferon Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2022-2027
  • Table 4.31: Enzyme Replacement and Other Protein Therapeutics Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 4.32: Enzyme Replacement and Other Protein Therapeutics Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%),2022-2027
  • Table 5.1: Regions of an Antibody
  • Table 5.2: Natural Antibody Mechanisms of Action
  • Table 5.3: Top Five Best-Selling Drugs, 2016: Revenue ($bn)
  • Table 5.4: Selected Biosimilar Adalimumab Candidates
  • Table 5.5: Humira Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 5.6: Humira Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2027
  • Table 5.7: Remicade 2016 Revenue Breakdown: Revenue ($bn), Percentage Change over 2016(%)
  • Table 5.8: Remicade Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2016-2021
  • Table 5.9: Remicade Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2022-2027
  • Table 5.10: Stelara Revenue 2014-2016:
  • Table 5.11: Total Tysabri Revenues 2012-2016, Revenues ($bn), AGR (%), CAGR (%)
  • Table 5.12: Tysabri Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 5.13: Tysabri Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2027
  • Table 5.14: Xolair Revenue Breakdown (between Roche and Novartis): Revenue ($bn), AGR (%), 2015-2016
  • Table 5.15: Selected Ongoing Sirukumab (CNTO-136) Clinical Trials, 2016
  • Table 5.16: Selected Ongoing Lebrikizumab Clinical Trials, 2016
  • Table 5.17: Selected Ongoing Anifrolumab Clinical Trials, 2016
  • Table 5.18: Herceptin Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2016-2021
  • Table 5.19: Herceptin Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2022-2027
  • Table 5.20: Kadcyla Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2016-2021
  • Table 5.21: Kadcyla Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2022-2027
  • Table 5.22: Perjeta Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 5.23: Perjeta Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2027
  • Table 5.24: FDA-Approved Indications for Cyramza
  • Table 5.25: Monoclonal Antibodies Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 5.26: Monoclonal Antibodies Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2027
  • Table 6.1: Amgen's US Patents and Expiry Dates for Enbrel
  • Table 6.1: Bristol-Myers Squibb's pipeline developments for Orencia
  • Table 6.2: Enbrel Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 6.3: Enbrel Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2022-2027
  • Table 6.4: Eylea Revenue Breakdown 201: Regeneron and Bayer
  • Table 6.5: Eylea Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 6.6: Eylea Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2027
  • Table 6.7: Fusion Proteins Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 6.8: Fusion Proteins Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2027
  • Table 7.1: Regenerative Medicines Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 7.2: Regenerative Medicines Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2027
  • Table 7.3: Potency and Source of Stem Cells
  • Table 7.4: Osteocel Plus Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 7.5: Osteocel Plus Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2022-2027
  • Table 7.6: Trinity Evolution and Trinity Elite Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2021
  • Table 7.7: Trinity Evolution and Trinity Elite Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027
  • Table 7.8: Stem Cell Therapies Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 7.9: Stem Cell Therapies Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2027
  • Table 7.10: Apligraf Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2021
  • Table 7.11: Apligraf Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027
  • Table 7.12: Dermagraft Revenue Forecast: Revenue ($m), AGR (%), CAGR (%),2016-2021
  • Table 7.13: Dermagraft Revenue Forecast: Revenue ($m), AGR (%), CAGR (%),2022-2027
  • Table 7.14: Tissue Engineering Therapies Submarket: Revenues ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 7.15: Tissue Engineering Therapies Submarket: Revenues ($bn), AGR (%), CAGR (%), 2022-2027
  • Table 7.16: IMLYGICRevenue Forecast: Revenue ($m), AGR (%), CAGR (%),2016-2021
  • Table 7.17: IMLYGICRevenue Forecast: Revenue ($m), AGR (%), CAGR (%),
  • Table 7.18: Gene Therapies Market Forecast: Revenue ($bn), AGR (%), CAGR (%),2016-2021
  • Table 7.19: Gene Therapies Market Forecast: Revenue ($bn), AGR (%), CAGR (%),2022-2027
  • Table 8.1: Regional Forecasts for the Global Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2021
  • Table 8.2: Regional Forecasts for the Global Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2022-2027
  • Table 8.3: US Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Global Market Share(%), 2016-2021
  • Table 8.4: US Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Global Market Share (%), 2022-2027
  • Table 8.5: European Biosimilar Approvals, 2006-2017
  • Table 8.6: EU5 Biologics Market: Revenues ($bn), AGR (%), CAGR (%), EU5 Market Share (%), 2016-2021
  • Table 8.7: EU5 Biologics Market: Revenues ($bn), AGR (%), CAGR (%), EU5 Market Share (%), 2022-2027
  • Table 8.8: Japanese Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Global Market Share (%), 2016-2021
  • Table 8.9: Japanese Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Global Market Share (%), 2022-2027
  • Table 8.10: BRIC Biologics Market: Revenues ($bn), AGR (%), CAGR (%), BRIC Market Share (%), 2016-2021
  • Table 8.11: BRIC Biologics Market: Revenues ($bn), AGR (%), CAGR (%), BRIC Market Share (%), 2022-2027

Companies Listed

  • 3SBio
  • AbbVie
  • Acceleron Pharma
  • Accord Healthcare
  • Aché
  • Actavis
  • Advanced BioHealing
  • Advantagene
  • Agência Nacional de Vigilância Sanitária (ANVISA)
  • Alder Biopharmaceuticals
  • Allergan
  • Alteogen
  • Amega Biotech
  • Amgen
  • AnGes
  • Anthera Pharmaceuticals
  • Apceth
  • Apotex
  • Aryogen
  • Astellas Pharma
  • AstraZeneca
  • Avita Medical
  • Baxalta
  • Baxter
  • Bayer
  • Beijing Four Rings
  • Beijing SL Pharmaceutical
  • Benda Pharmaceuticals
  • Biocad
  • BioCardia
  • Biocon
  • Biodel
  • Biogen
  • Bionovis
  • Biosidus
  • Biotest
  • Bioton
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • BrainStorm Cell Therapeutics
  • Bristol-Myers Squibb
  • Cambridge Antibody Technology
  • CCL Pharmaceuticals
  • Celgene Corporation
  • Celltrion
  • CEL-SCI
  • Centocor Ortho Biotech
  • Chugai
  • CinnaGen
  • ClinImmune Labs
  • CSL Behring
  • CT Arzneimittel
  • Cystic Fibrosis Foundation Therapeutics Inc
  • Dako
  • Dendreon
  • Dong-A
  • Dong-A Pharmaceutical
  • Dr. Reddy's Laboratories
  • Eli Lilly
  • EMA
  • Emcure Pharmaceuticals
  • EMS
  • Epirus
  • FDA
  • FibroGen
  • FierceBiotech
  • Finox Biotech
  • Fuji Pharma
  • Galencia
  • Gan & Lee
  • Genentech
  • GenSci
  • Gilead Sciences
  • GSK
  • Hangzhou Jiuyuan Gene Engineering Co.
  • Hanwha Chemical
  • Hexal
  • Hindustan Antibiotic
  • Histogenics
  • Hospira
  • Human Genome Sciences
  • Human Stem Cells Institute
  • Hypermarcas
  • Immunex Corporation
  • Innovare R&D
  • Intas Biopharmaceuticals
  • Ipsen
  • Janssen
  • JingYuan Bio
  • Johnson & Johnson
  • Kyowa Hakko Kirin
  • Laboratorios Delta
  • LG Life Sciences
  • LifeSouth Community Blood Centers
  • Medice
  • MEDICE Arzneimittel Pütter
  • MEDIPOST
  • Medtronic
  • Merck & Co.
  • Merck KGaA
  • Merz Pharma
  • Mitsubishi Tanabe
  • Mochida Pharmaceutical
  • Musculoskeletal Transplant Foundation (MTF)
  • Mylan
  • Nippion Kayaku
  • Novartis
  • Novo Nordisk
  • NuVasive
  • Oanda
  • Organogenes
  • OrLife Bio
  • Orthofix
  • Orygen
  • Pfizer
  • Pharmicell
  • Pharmstandard
  • Probiomed
  • Proteon Therapeutics
  • Qilu Pharmaceutical
  • Ranbaxy
  • Ratiopharm
  • Regeneron Pharmaceuticals
  • Regenerys
  • Reliance Life Sciences
  • Rentschler Biotechnologie.
  • Roche
  • Samsung Bioepis
  • Sandoz
  • Sanofi
  • Saudi Food and Drug Authority
  • Schering-Plough
  • SciGen
  • Shandong Kexing Pharma
  • Shanghai CP Guojian Pharmaceutical
  • Shanghai Fosun
  • Shanghai Sunway Biotech
  • Shantha Biotechnics
  • Shire
  • Sicor Biotech
  • Smith and Nephew
  • Spark Therapeutics
  • Stada
  • Stragen Pharma
  • Stratatech Corporation
  • Swiss Re
  • Teva
  • Tianjin Hualida Biotechnology
  • TiGenix
  • Tonghua Dongbao
  • UCB
  • União Química
  • UniQure
  • United Therapeutics
  • Vertex Pharmaceuticals
  • Vital Therapies Inc.
  • Wall Street Journal
  • Wockhardt
  • Wyeth-Ayerst Laboratories
  • Xiamen Amoytop Biotech
  • Zenotech
  • Zydus Biovation
  • Zydus Cadila

List of Organizations:

  • Central Drugs Standard Control Organisation
  • Children's Oncology Group
  • China Food and Drug Administration
  • CHMP
  • Duke University School of Medicine
  • European Federation of Pharmaceutical Industries and Associations
  • Europharm
  • Massachusetts General Hospital
  • New York Blood Center
  • NHS
  • NICE
  • SSN Cardinal Glennon Children's Medical Center
  • Stanford University
  • The European Generic medicines Association (EGA)
  • The European Group for Blood and Marrow Transplantation (EBMT)
  • Toronto University
  • UCSF (University of California, San Francisco)
  • University of Colorado Cord Blood Bank
  • University of Tokyo
  • US Center for Disease Prevention and Control (CDC)
  • Walter and Eliza Hall Institute
  • World Bank
  • Yonsei University
Back to Top